Quantum BioPharma (NASDAQ: QNTM) has entered into a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial, according to a NEWMEDIAWIRE press release. Thermo Fisher will support study start-up and related clinical research services through its PPD™ Clinical Research Business.
Quantum BioPharma said the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation.
This news is significant for the multiple sclerosis community, as progressive forms of MS currently have limited treatment options. If successful, Lucid-MS could become a first-in-class therapy that addresses the underlying mechanism of myelin degradation, potentially slowing or reversing disease progression. For Quantum BioPharma, a successful trial could validate its lead compound and open doors to partnerships or commercialization, enhancing shareholder value. The involvement of Thermo Fisher's PPD clinical research business adds credibility and operational expertise to the trial.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
To view the full press release, visit https://ibn.fm/CZH9U. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
Forward-looking statements in the press release note that risks and uncertainties could cause actual results to differ materially from expectations. Investors are cautioned not to place undue reliance on such statements. The trial's progress will be closely watched as a potential breakthrough for progressive MS, a condition with high unmet need. For more details, see the original release on www.newmediawire.com.
